BlackRock Inc. purchased a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 26,711,079 shares of the medical instruments supplier's stock, valued at approximately $283,405,000. BlackRock Inc. owned approximately 13.33% of DENTSPLY SIRONA as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also bought and sold shares of XRAY. Southpoint Capital Advisors LP bought a new position in DENTSPLY SIRONA during the 1st quarter valued at $116,000,000. AQR Capital Management LLC raised its holdings in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the period. Armistice Capital LLC grew its stake in shares of DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier's stock worth $72,790,000 after acquiring an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier's stock worth $58,480,000 after buying an additional 4,003,606 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock valued at $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Institutional investors own 95.70% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on XRAY shares. Barrington Research set a $15.00 target price on DENTSPLY SIRONA in a research note on Monday, August 10th. BMO Capital Markets restated a "market perform" rating and issued a $13.00 price objective on shares of DENTSPLY SIRONA in a report on Friday, August 7th. Mizuho lowered their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, May 6th. Piper Sandler increased their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a "neutral" rating in a report on Wednesday, July 29th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, DENTSPLY SIRONA presently has a consensus rating of "Hold" and a consensus target price of $13.54.
Check Out Our Latest Report on XRAY
DENTSPLY SIRONA Price Performance
Shares of NASDAQ:XRAY opened at $10.93 on Thursday. DENTSPLY SIRONA Inc. has a 1-year low of $9.40 and a 1-year high of $14.86. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. The business has a fifty day moving average price of $12.07 and a 200-day moving average price of $11.77. The company has a market capitalization of $2.18 billion, a PE ratio of -3.97, a PEG ratio of 1.38 and a beta of 0.85.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.17. The company had revenue of $898.00 million for the quarter, compared to analysts' expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. DENTSPLY SIRONA's revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts expect that DENTSPLY SIRONA Inc. will post 1.41 EPS for the current fiscal year.
Insider Transactions at DENTSPLY SIRONA
In other news, Director Michael J. Barber acquired 15,175 shares of the firm's stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the acquisition, the director directly owned 55,943 shares in the company, valued at approximately $552,716.84. The trade was a 37.22% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brian T. Gladden acquired 9,985 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was acquired at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the transaction, the director directly owned 61,849 shares in the company, valued at $619,726.98. This represents a 19.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 35,160 shares of company stock worth $351,179. Corporate insiders own 0.46% of the company's stock.
DENTSPLY SIRONA Company Profile
(
Free Report)
Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Further Reading
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider DENTSPLY SIRONA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.
While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
